Imatinib Koanaa 100 Mg

Imatinib mesilate, the active ingredient in Imatinib Koanaa 100 Mg, is a tyrosine kinase inhibitor presented as a 100 mg oral tablet for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Koanaa 100 Mg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib Koanaa targets BCR‑ABL and related tyrosine kinases in hematologic and solid tumours.

- Chronic myeloid leukemia (CML): reduces malignant cell proliferation and improves survival in patients with BCR‑ABL positive disease. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): achieves remission by targeting BCR‑ABL driven leukemic cells. - Gastrointestinal stromal tumor (GIST): inhibits c‑KIT and PDGFR signaling to control tumor growth.

Imatinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Peripheral edema: swelling of hands, feet or ankles. - Muscle cramps or pain: especially in the lower limbs. - Fatigue: generalized tiredness. - Diarrhoea: loose stools. - Rash: skin irritation or redness.

Serious or Rare Side Effects: - Neutropenia or severe leukopenia: increased infection risk. - Thrombocytopenia: bleeding tendency. - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac failure: reduced heart function, especially in patients with pre‑existing disease. - Pulmonary hypertension: elevated pressure in lung arteries. - Severe haemorrhage: uncommon but potentially life‑threatening bleeding.

Before and during treatment, careful monitoring and patient education are essential.

- Monitor blood counts: perform regular CBC to detect cytopenias. - Assess liver function: evaluate hepatic enzymes before and during therapy. - Check cardiac status: be cautious in patients with pre‑existing heart disease. - Avoid in severe infection: postpone treatment if active infection is present. - Pregnancy and lactation: use only if benefits outweigh risks, as safety is unknown. - Store at ambient temperature below 25 °C: keep in original container, protect from moisture and light.

Imatinib interacts with several drug classes; awareness helps avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - CYP3A4 strong inhibitors (e.g., ketoconazole, clarithromycin): may increase imatinib exposure and toxicity. - CYP3A4 inducers (e.g., rifampicin, phenytoin): may reduce efficacy. - Antacids containing aluminum or magnesium: decrease absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - Proton pump inhibitors: may modestly affect plasma levels, monitor clinical response. - Live attenuated vaccines: consider timing due to immunosuppression.